Learn more

ONCONOVA THERAPEUTICS INC

Overview
  • Total Patents
    99
  • GoodIP Patent Rank
    72,596
  • Filing trend
    ⇧ 175.0%
About

ONCONOVA THERAPEUTICS INC has a total of 99 patent applications. It increased the IP activity by 175.0%. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are ABERG GUNNAR, KALVINSH IVARS and ORATECH PHARM DEV CORP.

Patent filings per year

Chart showing ONCONOVA THERAPEUTICS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Maniar Manoj 57
#2 Bell Stanley C 42
#3 Reddy M V Ramana 18
#4 Reddy E Premkumar 8
#5 Wilhelm Francois 7
#6 Raza Azra 7
#7 Kumar Ramesh 7
#8 Reddy Ramana M V 6
#9 Wong Albert 5
#10 Tycko Benjamin 4

Latest patents

Publication Filing date Title
WO2020101638A1 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders
TW202017571A 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenyl amino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders
WO2018190897A1 Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
US2016102363A1 Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders
WO2014089483A1 Methods and compositions for treatment of cancer
CA2792913A1 Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
EP2549867A1 Compositions and methods for prevention and treatment of wounds
EP2373993A2 Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
IL189063D0 Pharmaceutical composition for reducing toxic effects of ionizing radiation comprising carbostyryl-chlorobenzylsulfone, modified cyclodextrin, a water soluble polymer and n,n- dimethylacetamide
CA2675374A1 Formulations for parenteral administration of amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
CA2663375A1 Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
US2009247624A1 Formulations of radioprotective alpha beta unsaturated aryl sulfones
AU2006275822A1 Formulation of radioprotective alpha, beta unsaturated aryl sulfones
AU2006216544A1 Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
CA2574491A1 Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
NZ583093A Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US7161031B2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
AU2002337843A1 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
EP1436285A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
AU2002330042A1 Process for the preparation of 1,5-diarylpyrazoles